CN104592091B - 一种含吲哚乙酸核心结构的化合物及其应用 - Google Patents

一种含吲哚乙酸核心结构的化合物及其应用 Download PDF

Info

Publication number
CN104592091B
CN104592091B CN201510040470.5A CN201510040470A CN104592091B CN 104592091 B CN104592091 B CN 104592091B CN 201510040470 A CN201510040470 A CN 201510040470A CN 104592091 B CN104592091 B CN 104592091B
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutically acceptable
compounds
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510040470.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104592091A (zh
Inventor
冉瑞琼
邓廉夫
李玉明
周欣
李瀚旻
王海勇
唐国涛
赵子淏
王健生
袁定清
王建华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing An Jianxi Medical Science And Technology Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201510040470.5A priority Critical patent/CN104592091B/zh
Publication of CN104592091A publication Critical patent/CN104592091A/zh
Priority to PCT/CN2016/071934 priority patent/WO2016119643A1/zh
Priority to EP21203847.5A priority patent/EP3978473B1/en
Priority to AU2016212552A priority patent/AU2016212552B2/en
Priority to US15/547,013 priority patent/US10494341B2/en
Priority to EP16742705.3A priority patent/EP3252039B1/en
Priority to KR1020177021530A priority patent/KR101975299B1/ko
Priority to JP2017540779A priority patent/JP6442615B2/ja
Application granted granted Critical
Publication of CN104592091B publication Critical patent/CN104592091B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201510040470.5A 2015-01-27 2015-01-27 一种含吲哚乙酸核心结构的化合物及其应用 Active CN104592091B (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201510040470.5A CN104592091B (zh) 2015-01-27 2015-01-27 一种含吲哚乙酸核心结构的化合物及其应用
US15/547,013 US10494341B2 (en) 2015-01-27 2016-01-25 Compound containing indoleacetic acid core structure and use thereof
EP21203847.5A EP3978473B1 (en) 2015-01-27 2016-01-25 Compound containing an indoleacetic acid core structure and use thereof
AU2016212552A AU2016212552B2 (en) 2015-01-27 2016-01-25 Compound containing indoleacetic acid core structure and use thereof
PCT/CN2016/071934 WO2016119643A1 (zh) 2015-01-27 2016-01-25 一种含吲哚乙酸核心结构的化合物及其应用
EP16742705.3A EP3252039B1 (en) 2015-01-27 2016-01-25 Compound containing indoleacetic acid core structure and use thereof
KR1020177021530A KR101975299B1 (ko) 2015-01-27 2016-01-25 인돌아세트산의 코어구조를 함유하는 화합물 및 그의 용도
JP2017540779A JP6442615B2 (ja) 2015-01-27 2016-01-25 インドール酢酸コア構造を含む化合物とその応用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510040470.5A CN104592091B (zh) 2015-01-27 2015-01-27 一种含吲哚乙酸核心结构的化合物及其应用

Publications (2)

Publication Number Publication Date
CN104592091A CN104592091A (zh) 2015-05-06
CN104592091B true CN104592091B (zh) 2017-07-04

Family

ID=53118197

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510040470.5A Active CN104592091B (zh) 2015-01-27 2015-01-27 一种含吲哚乙酸核心结构的化合物及其应用

Country Status (7)

Country Link
US (1) US10494341B2 (enExample)
EP (2) EP3252039B1 (enExample)
JP (1) JP6442615B2 (enExample)
KR (1) KR101975299B1 (enExample)
CN (1) CN104592091B (enExample)
AU (1) AU2016212552B2 (enExample)
WO (1) WO2016119643A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104592091B (zh) * 2015-01-27 2017-07-04 冉瑞琼 一种含吲哚乙酸核心结构的化合物及其应用
CN109180521B (zh) * 2018-09-05 2021-08-31 中国人民解放军陆军军医大学 一种抗肿瘤化合物及其制备方法、用途
US12186332B2 (en) * 2019-06-27 2025-01-07 Stowers Institute For Medical Research Methods for overcoming WNT/beta-catenin anti-cancer resistance in leukemia stem cells
CA3235127A1 (en) * 2021-10-15 2023-04-20 Yao XU 2,3-dimethoxy-5-methyl-1,4-benzoquinone alkyl alcohol derivative and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654349A (en) * 1970-05-01 1972-04-04 Merck & Co Inc Substituted indenyl acetic acids
CN1237162A (zh) * 1996-11-12 1999-12-01 美国家用产品公司 Cox－2的茚抑制剂
WO2006099416A1 (en) * 2005-03-11 2006-09-21 Nitromed, Inc. 2-methyl indole cyclooxygenase-2 selective inhibitors, compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643943A (en) * 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
WO2014138922A1 (en) * 2013-03-15 2014-09-18 Indanio Bioscience Inc. Uses for idebenone and related benzoouinones in ppar-related diseases and conditions
CN104592091B (zh) 2015-01-27 2017-07-04 冉瑞琼 一种含吲哚乙酸核心结构的化合物及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654349A (en) * 1970-05-01 1972-04-04 Merck & Co Inc Substituted indenyl acetic acids
CN1237162A (zh) * 1996-11-12 1999-12-01 美国家用产品公司 Cox－2的茚抑制剂
WO2006099416A1 (en) * 2005-03-11 2006-09-21 Nitromed, Inc. 2-methyl indole cyclooxygenase-2 selective inhibitors, compositions and methods of use

Also Published As

Publication number Publication date
US10494341B2 (en) 2019-12-03
JP6442615B2 (ja) 2018-12-19
US20180022700A1 (en) 2018-01-25
EP3252039B1 (en) 2021-11-03
EP3252039A1 (en) 2017-12-06
KR20170129688A (ko) 2017-11-27
EP3978473B1 (en) 2026-05-06
AU2016212552B2 (en) 2018-10-25
WO2016119643A1 (zh) 2016-08-04
CN104592091A (zh) 2015-05-06
EP3978473A1 (en) 2022-04-06
AU2016212552A1 (en) 2017-08-17
KR101975299B1 (ko) 2019-05-07
JP2018505184A (ja) 2018-02-22
EP3252039A4 (en) 2018-07-25

Similar Documents

Publication Publication Date Title
AU2008286954B2 (en) Anti-inflammatory compounds and uses thereof
US20090227542A1 (en) Novel Boronic Chalcone Derivatives and Uses Thereof
RU2657750C1 (ru) Новые способы направленного воздействия на раковые стволовые клетки
US20120035255A1 (en) Derivative of [(3-hydroxy-4 pyron-2-yl)-methyl]-amine and use thereof as anti-neoplastic drugs
WO2009124460A1 (zh) 雷公藤二萜类内酯衍生物、其药物组合物及其在抗生殖系统肿瘤中的应用
JP6442615B2 (ja) インドール酢酸コア構造を含む化合物とその応用
Gond et al. Mn (II) catalyzed synthesis of 5 (4-hydroxyphenyl)-2-(N-phenylamino)-1, 3, 4-oxadiazole: crystal structure, DFT, molecular docking, Hirshfeld surface analysis, and in vitro anticancer activity on DL cells
CN110002987A (zh) 苯基亚烯丙基环己烯酮衍生物及制备方法和用途
Liu et al. Use of cucurbitacins for lung cancer research and therapy
Li et al. A Pt (IV)-based mononitro-naphthalimide conjugate with minimized side-effects targeting DNA damage response via a dual-DNA-damage approach to overcome cisplatin resistance
US20240100066A1 (en) ORAL Pt (IV) ANTICANCER PRODRUG CONTAINING 3-BROMOPYRUVATE AS AXIAL LIGAND
Zhu et al. Real-time monitoring of etoposide prodrug activated by hydrogen peroxide with improved safety
Swain et al. Preparation of dendritic carboranyl glycoconjugates as potential anticancer therapeutics
US11117907B2 (en) Curcuminoid-inspired synthetic compounds as anti-tumor agents
Liu et al. Synthesis of a celastrol derivative as a cancer stem cell inhibitor through regulation of the STAT3 pathway for treatment of ovarian cancer
WO2025093671A2 (en) Sulforaphane analogues (sfnas) as well as cd/sfnas inclusion complexes and uses thereof
EP2902388B1 (en) Condensation product of theanine derivative and carboxylic acid coumarin derivative, intermediate of the condensation product, method for preparing same, and use thereof
HK40070404A (en) Compound containing an indoleacetic acid core structure and use thereof
CN108473449B (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的砜脒及其制备方法和用途
HK1241872A1 (en) Compound containing indoleacetic acid core structure and use thereof
HK1241872B (en) Compound containing indoleacetic acid core structure and use thereof
JPWO2007066557A1 (ja) ホスフィン遷移金属錯体、その製造方法およびそれを含有する抗癌剤
JP7844361B2 (ja) 修飾単糖化合物を使用してがんを治療する方法
Cheng et al. Synthesis of Curcumin-ferulic acid conjugate via Steglich esterification and anti-lung cancer activity of against Human non-small lung cancer cells (NSLCC)
CN103736099B (zh) 硝基苯基烷酸与碱性抗肿瘤药物连接的前体药物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20161024

Address after: 430075 No. 666, hi tech Avenue, East Lake Development Zone, Hubei, Wuhan

Applicant after: Ran Ruiqiong

Applicant after: Xu Yao

Address before: 430075 No. 666, hi tech Avenue, East Lake Development Zone, Hubei, Wuhan

Applicant before: Ran Ruiqiong

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20171108

Address after: 100036 Beijing city Haidian District Cuiwei Road No. 2 on Printing No. 5 X301

Patentee after: Beijing An Jianxi medical science and Technology Co., Ltd.

Address before: 430075 No. 666, hi tech Avenue, East Lake Development Zone, Hubei, Wuhan

Co-patentee before: Xu Yao

Patentee before: Ran Ruiqiong

TR01 Transfer of patent right